Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $19
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $15 to $19.
Read original at benzingaStocks · News reference
Fulgent Genetics shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 adjusted EPS and FY2026 sales guidance.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 30, 2026, 8:51 PM
- Checked
- Jul 30, 2026, 8:51 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Fulgent Genetics shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 adjusted EPS and FY2026 sales guidance.
Read original at benzingaApple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analyst estimates for Q3. Other stocks also dip in pre-market.
Read original at benzingaFulgent Genetics Lowers FY2026 Adj EPS Guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) Est; Lowers FY2026 Sales Guidance from $350.000M to $330.000M-$340.000M vs $351.900M Est
Read original at benzinga